Failure to provide public funding for clinical trials may come at a high cost to the community in the long term
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- Department of Epidemiology and Preventive Medicine, Monash Medical School, Alfred Hospital, Prahran, VIC.
Correspondence:
- 1. Reid CM, Wing LM, Graham DH. A new paradigm for funding cardiovascular-outcome research in general practice. The Second Australian National Blood Pressure Study. Med J Aust 1998; 169: 349-350.
- 2. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326: 1167-1170.
- 3. Australian Department of Health and Ageing. Pharmaceutical Benefits Scheme. Table 10(a): Significant drug groups by highest government cost. Available at: www.health.gov.au/pbs/general/pubs/pbbexp/pbjun03/pdf/book23.pdf (accessed Sep 2003).
- 4. Nelson MR, McNeil JJ, Peeters A, et al. PBS/RPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension in Australia, 1994–1998. Med J Aust 2001; 174: 565-568.
- 5. Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-592.
- 6. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
- 7. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321-333.
- 8. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 update. Circulation 2002; 106: 388-391.
- 9. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials [comment]. JAMA 1998; 280: 1930-1935.
- 10. Hernandez-Diaz S, Rodriguez LA. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol 2002; 55: 157-163.
Online responses are no longer available. Please refer to our instructions for authors page for more information.